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SUMMARY
We previously described a mouse model of ulcerative colitis linked to T-bet deficiency in the innate immune
system. Here, we report that the majority of T-bet/ RAG2/ ulcerative colitis (TRUC) mice spontaneously
progress to colonic dysplasia and rectal adenocarcinoma solely as a consequence of MyD88-independent
intestinal inflammation. Dendritic cells (DCs) are necessary cellular effectors for a proinflammatory program
that is carcinogenic.Whereas thesemalignancies arise in the setting of a complex inflammatory environment,
restoration of T-bet selectively in DCs was sufficient to reduce colonic inflammation and prevent the devel-
opment of neoplasia. TRUC colitis-associated colorectal cancer resembles the human disease and provides
ample opportunity to probe how inflammation drives colorectal cancer development and to test preventative
and therapeutic strategies preclinically.INTRODUCTION
The three highest risk groups for developing colorectal cancer
(CRC) are individuals with ulcerative colitis (UC), familial adeno-
matous polyposis, and hereditary nonpolyposis colon cancer
syndrome. Among UC patients, the relative risk of developing
CRC correlates with the extent and duration of disease—18%
will have developed CRC after 30 years of disease (Eaden
et al., 2001; Xie and Itzkowitz, 2008). The sequence of genetic
events in colitis-associated CRC (caCRC) differs from that
observed in sporadic CRC. In caCRC, chromosomal instability
(CIN) and DNA damage can precede and predict the develop-
ment of dysplasia, and alterations in p53 expression occur early208 Cancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Incin the oncogenic pathway, not as is depicted in the classic
adenoma-carcinoma sequence (Cho and Vogelstein, 1992; Clau-
sen et al., 2001; Itzkowitz, 2003; Yoshida et al., 2003). In addition,
in contrast to sporadic CRC, alterations in b-catenin localization
reflecting APC mutations occur very late in the caCRC transfor-
mation process. Sporadic CRC carcinogenesis is typified by
the transformation of the adenoma to an adenocarcinoma
(ACA); however, in caCRC, invasive carcinomas frequently arise
in flat areas of dysplasia. This feature of caCRC makes clinical
surveillance of this at risk population particularly challenging
and speaks to the distinct biology of these neoplasias.
Mouse models of intestinal cancer have been instrumental in
understanding oncogenesis and have shed light on the role ofSIGNIFICANCE
Inflammatory bowel disease (IBD) is one of the three highest risk factors for colorectal cancer (CRC). The molecular
pathogenesis of IBD-associated colorectal cancer (caCRC) differs from that of sporadic CRC. The findings reported here
demonstrate that the T-bet/ RAG2/ ulcerative colitis model of caCRC is a robust system for studying the human
disease. This model establishes the importance of the innate immune system and specifically dendritic cells as key cellular
effectors in inflammation that drives neoplasia. Our data also demonstrate that there areMyD88-independent pathways to
caCRC. Finally, the observation that overexpression of T-bet in innate immune cells prevents caCRC provides an additional
explanation for why colorectal cancer patients with intratumoral T-bet expression may have improved survival and
generates interest in immune-based cancer therapeutics..
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Colitis-Associated Colorectal Cancer in TRUC Miceinnate immunity and the commensal microbiota in colon cancer.
We recently described a model of commensal-dependent UC
termed T-bet/ RAG2/ UC (TRUC) that results from T-bet
deficiency in the innate immune system (Garrett et al., 2007).
T-bet is a T-box family transcription factor that controls chemo-
kine, chemokine receptor, and cytokine expression; regulates
host-commensal homeostasis in the colon; and is expressed
only in immune cells (Glimcher, 2007; Ma, 2007). TRUC mice
develop a severe and highly penetrant colitis, driven in part by
loss of TNF-a regulation in the colon, that can be reversed by
antibiotics, TNF-a blockers, or transfer of T regulatory cells.
CRC has been documented in other inflammatory bowel disease
(IBD) mouse models including IL-10/, TCRa/, Gai2/,
IL-2/ 3 b2m/, and av/ mice (Berg et al., 1996; Dianda
et al., 1997; Lacy-Hulbert et al., 2007; Rudolph et al., 1995;
Shah et al., 1998). This observation coupled with the finding
that increased levels of T-bet in human colorectal tumors corre-
late with increased patient survival spurred us to determine if
TRUC mice, whose colitis is mechanistically distinct from other
IBD models, would develop caCRC (Pages et al., 2005).
RESULTS
TRUC Mice Develop Dysplasia and Carcinoma
Resembling Human IBD-Associated CRC
In our colony, TRUC manifests a juvenile colitis that starts
rectally, has 100% penetrance, and can result in bacteremia
and death as early as 10 weeks of age. We monitored large
cohorts (>400 TRUC mice during a 3 year period) to robustly
survey whether dysplasia and carcinoma would develop over
time. At 3 months of age, 50% of TRUC mice had dysplastic
lesions and ACA was present in 3/40 cases. By 6 months of
age, over 96% of mice had dysplastic lesions and 42% had
ACA (Figure 1A). Low-grade dysplasia (LGD) predominated in
younger mice (75% of cases), while 6 month olds manifested
high-grade dysplasia (HGD) (89% of cases) (Figure 1B). In 12/
30 of the HGD cases there were adjacent regions of LGD (1–
3 mm) (data not shown), suggesting progression to the higher
grade. Similarly, ACA (size range 2–7 mm) were flat and usually
arose in the rectum within regions of dysplastic mucosa (25/31
cases), similar to what is observed in UC patients. The number
of mice with more advanced submucosal invasive cancers
increased over time (Figure 1C). Hence, malignant transforma-
tion of intestinal epithelial cells occurs in virtually all TRUC
mice by 6 months of age and progresses to frank ACA in a signif-
icant proportion of animals.
On gross examination, areas of colitis with dysplasia and ACA
appeared more vascular and engorged as compared with colons
with similar inflammatory scores but no dysplasia or cancer
(Figure 1D). We noted the occurrence of fixed anorectal prolapse
as it can complicate the diagnosis of cancer and dysplasia (10/
21 intramucosal and 2/10 submucosal ACA cases). Photomicro-
graphs are shown from representative cases with carcinoma
(Figure 1E, upper panel; dysplasia [middle panel: left, HGD; right,
LGD], and no dysplasia [bottom panel: left, colitis; right, no colitis]).
Immunohistochemistry for PCNA revealed a high degree of
proliferation in mice with ACA and dysplasia, consistent with
neoplastic transformation (Figure 1F, upper left panel). To deter-
mine whether TRUC caCRC phenotypically resembled humanCcaCRC, we assessed the expression of additional markers by
immunohistochemistry. Similar to human caCRC, and in con-
trast to what is observed in sporadic CRC, b-catenin localization
was membranous in nondysplastic and dysplastic lesions
(Figure 1F, upper right panel) and nuclear (indicative of APC
loss of function) in carcinoma (Figure 1F, upper right panel). As
is observed in human caCRC, we saw high levels of epithelial
cell and immune cell COX-2 expression in inflamed mucosa
that was nonneoplastic and neoplastic (Figure 1F, middle panel)
(Agoff et al., 2000). Approximately 30% of nonneoplastic crypts
were positive for COX-2 and >90% of neoplastic crypts were
positive (Figure 1F, middle panel); thus COX-2 epithelial expres-
sion is a premalignant feature of TRUC transformation. Intense
nuclear staining for p53 (CM5 clone: detects both mutant and
wild-type forms) was detected in the neoplastic epithelium and
in nondysplastic crypts; an observation that is highly suggestive
of p53 mutations (Rodrigues et al., 1990) (Figure 1F, bottom
panel). To assess if this increased p53 expression was a conse-
quence of mutations resulting in loss of p53 function, we per-
formed two complementary experiments examining both the
DNA binding capability of p53 and induction of p53 target genes.
Specifically, we tested p53 DNA binding activity and expression
of the p53 target genes, p21 and APAF1, in colonic epithelial
cells (CECs) from control, nonneoplastic TRUC, and neoplastic
TRUC in response to treatment with doxorubicin, an anthracy-
cline chemotherapeutic that inhibits topoisomerase II, induces
double-stranded DNA breaks, and strongly activates p53 (Rav-
izza et al., 2004). Doxorubicin treatment induced p53 binding
to a consensus site oligonucleotide in RAG2/ (control) CECs
in a specific fashion but was reduced in TRUC nonneoplastic
CECs and markedly diminished in neoplastic TRUC CECs
(Figure 1G, upper panel). p21 expression was induced approxi-
mately 250-fold in RAG2/ CECs treated with doxorubicin;
however, this induction was more modest in TRUC nonneoplas-
tic CECs (70.2-fold) and substantially reduced in neoplastic
TRUC CECs (2.23-fold) (Figure 1G, lower left panel). APAF1
levels in response to doxorubicin were upregulated most in
RAG2/ (1321-fold), approximately an order of magnitude
less in TRUC nonneoplastic (100.3-fold) and substantially
reduced in TRUC neoplastic (1.42-fold) samples (Figure 1G,
lower right panel). Thus the TRUC neoplastic process does
resemble human caCRC in several aspects of its molecular path-
ogenesis, specifically in both early loss of function of p53 and
increased epithelial COX-2 expression and later APC mutations.
TRUC Mice Develop Colonic Epithelial Aneuploidy prior
to Dysplasia, and the TRUC Mucosa Is Rich in ROS,
Colonic Epithelial DNA Adducts, and Cytokines, Similar
to IBD Patients Who Develop Dysplasia and Cancer
CIN and its resulting aneuploid DNA content are features of
human caCRC. In fact, CIN has been detected in UC patient
colonic biopsies that are nondysplastic, dysplastic, and malig-
nant; and aneuploidy predicts dysplasia (Clausen et al., 2001;
Meling et al., 1991a, 1991b; Rubin et al., 1992). To search for
CIN and aneuploidy in TRUC mice with and without dysplasia
and cancer, we measured DNA content in CECs from TRUC
colons by flow cytometry. While no aneuploid cell populations
were detected in 6 month old RAG2/ mice (data not shown),
aneuploidy was a feature of nondysplastic and dysplasticancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc. 209
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Figure 1. TRUC Mice Develop caCRC
(A) Percentage of TRUC mice with and without dysplasia and cancer is shown as a function of mouse age (in months). The number of mice surveyed is displayed
along the x axis. No cancers were observed in age-matched RAG2/ (data not shown).
(B) Dysplastic grade is shown as a percentage of dysplastic cases for mice at 3, 4, and 6 months. Size (mm) of low- and high-grade dysplastic lesions is displayed
for each animal.
(C) Level of invasion (intramucosal versus submucosal) is shown as a percentage of carcinoma cases. Lesion size (mm) of the carcinomas (shaded bars) and
continuous areas of dysplasia (open bars) are plotted for individual cases.
(D) Photographs of TRUC colons with colitis but no dysplasia (left) and with CRC (right).
(E) Histology from TRUC mice with invasive carcinoma (upper panel), dysplasia (middle panel [left: HGD, right: LGD]), and no dysplasia (lower panel [left: colitis,
no dysplasia, right: no colitis, no dysplasia]). Scale bars, 100 mm.
(F) Immunohistochemistry. (left upper panel) PCNA. Scale bars, 100 mm. (right upper panel) b-Catenin staining in dysplastic epithelial crypts (left) and nuclear
staining in invasive carcinoma (right). Scale bars, 25 mm. COX-2 (left middle panel) and quantitation of COX-2+ crypts (right middle panel). Scale bars, 100 mm.
P53 (left lower panel, nuclear staining in crypts) and quantitation of p53 staining (right lower panel); each dot represents data from one mouse. Scale bars, 25 mm.
(G) Colonic epithelial p53 activity induced by doxorubicin. (left upper panel) Consensus oligonucleotide binding activity of p53 in nuclear extracts of CECs from
RAG2/ versus TRUC nonneoplastic versus TRUC neoplastic colons. Gray bars are from untreated samples, black bars are from doxorubicin-treated CECs
incubated with biotinylated oligonucleotides, and open bars are from doxorubicin-treated CECs incubated with biotinylated and 20-fold excess unbiotinylated
oligonucleotides. Data represent the mean of two independent experiments with primary epithelial cells pooled from 20 mice per group (RAG2/, TRUC non-
neoplastic, and TRUC neoplastic). Error bars denote ± SD. (left lower panel) p21 induction in response to doxorubicin. Real-time qPCR was performed on control
and doxorubicin-treated samples. Fold change between doxorubicin and untreated samples was calculated by dividing their respective 2DCt values. (right
lower panel) APAF1 induction in response to doxorubicin was determined on the same sample set as above. Bars represent the mean of two independent exper-
iments and error bars the ± SD.TRUC colons and was most pronounced in those with dysplasia
and cancer (mean 2.34% [nonneoplastic] versus 6.11%
[neoplastic], p = 0.0005) (Figure 2A).210 Cancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier IncAlthough the exact mechanisms by which inflammation drives
CIN remain controversial, there is more consensus regarding
how other types of DNA damage, e.g., DNA adducts, occur in.
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Colitis-Associated Colorectal Cancer in TRUC Micethe setting of inflammation. Reactive oxygen species (ROS) and
other oxidative stressors drive DNA damage by oxidizing DNA
bases and generating DNA adducts at a rate that outpaces
DNA repair mechanisms. ROS and DNA adducts have been
well characterized in IBD patients and in animal models of intes-
tinal inflammation (D’Inca et al., 2004). We found that the TRUC
inflammatory milieu was rich in ROS and that increased ROS
levels correlated with TRUC carcinogenesis (Figure 2B). To
determine if DNA adducts were an untoward consequence of
ROS we measured levels of 8-hydroxy-2-deoxyguanine in
TRUC CECs. We found that DNA adducts were detectable in
young TRUC and aged RAG2/ mice; however, the levels of
these adducts increased 3-fold between 1 and 2 months in
TRUC mice and were highest in 4 and 6 month old TRUC mice
C
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Figure 2. Chromosomal Instability and
Reactive Oxygen Induced DNA Adducts in
TRUC Carcinogenesis
(A) Flow cytometric aneuploidy analysis of epithe-
lial cells isolated from mice without dysplasia,
with dysplasia, and with carcinoma. (left panel)
Representative plot from one mouse with diploid
and aneuploid populations labeled. (right panel)
Percentage of aneuploid epithelial cells for all
mice analyzed. Each dot represents data from
one mouse. Horizontal bars represent the mean.
(B) ROS were measured in TRUC versus RAG2/
distal colons. Reactive luminescence measured in
units/second/milligram of colonic tissue 3 1000
(y axis) is plotted as a function of mouse age.
Open bars show RAG2/ and shaded bars
show TRUC (five to eight mice per group). Means
are graphed; error bars represent ± SD, p <
0.001 for all comparison between TRUC 1 month
and TRUC 2–6 months.
(C) 80hydroxy-20deoxyguanine (ng/ml) levels in
CECs. RAG2/ control (age 1 and 6 months,
open bars, n.d. = not performed for RAG2/ [age
2–4 months]) and TRUC mice (age 1–6 months,
shaded bars). Six to nine mice were used per time
point. Means are graphed; error bars represent ±
SD, p < 0.001 for all comparison between TRUC
1 month and TRUC 2–6 months.
(D) ELISA-based protein determinations for
selected cytokines are shown from explant
cultures pooled from five to seven specimens
per time point from RAG2/ versus TRUC colitic
(nonneoplastic) versus TRUC dysplastic versus
TRUC carcinoma. Bars represent the mean values
for three independent sets of pooled samples and
error bars represent ± SD.
(enriched for dysplasia and carcinoma)
(p < 0.001, for all TRUC comparisons 1
month versus 2–6 months) (Figure 2C).
The inflammatory microenvironment was
rich in several cytokines (e.g., IL-1b,
TNF-a, IL-6, IFNg, and IL-10), many of
which increased in colonic explant
cultures with dysplasia and carcinoma
(Figure 2D). We have examined the
expression of a number of cytokines,
proinflammatory mediators, growth fac-
tors, and proteases and found that the vast majority increased
in the transition from colitis to dysplasia and colitis to carcinoma
(see Figures S1A and S1B available online). Thus the chronically
inflamed TRUC mucosa is a prooncogenic environment rich in
ROS, DNA adducts, as well as numerous cytokines and growth
factors with mitogenic potential.
Unbalanced Epithelial Cell Death and Proliferation
in TRUC Mice
At its core this upregulation of cytokines, proteases, and growth
factors represents a repair response; however, in the setting of
ROS and CIN a prooncogenic environment is the result. We
investigated the response of the epithelium to this environment
by carefully interrogating epithelial cell proliferation and cellCancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc. 211
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Colitis-Associated Colorectal Cancer in TRUC Micedeath. We found that the TRUC epithelium became increasingly
hyperproliferative with time (Figures 3A and 3B). Furthermore,
quantifying cell death in the epithelium by TUNEL staining and
proliferation by BrDU staining revealed marked imbalances
between cell death and proliferation in the TRUC epithelium. At
4 weeks of age, cell death outpaced the proliferative response.
However, once initiated, the repair response surpassed a
homeostatic level of epithelial maintenance, even considering
the increase in regenerative activity secondary to colitis (Fig-
ure 3C). It was possible that the TRUC inflammatory milieu also
altered the balance of apoptotic and antiapoptotic proteins in
the epithelium as evidenced by imbalances in the expression
of proteins regulating apoptosis and hyperproliferation. Western
blot analysis of Bcl-2 family members in CEC extracts from
TRUC samples across the neoplastic continuum and from
RAG2/ samples revealed increased antiapoptotic Bcl-2 in
dysplastic samples versus nondysplastic samples and de-
creased proapoptotic Bak in samples with HGD and cancer
(Figure 3D). Alterations in Bcl-2 and Bak levels accompany the
hyperproliferation and decreased cell death observed during
TRUC neoplastic transformation. The ROS of the inflammatory
environment may exert selective pressure on the epithelium
and epithelial cells with reduced apoptotic potential, due to
increased Bcl-2 and decreased Bak, may have a survival
advantage.
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Figure 3. Imbalance between Cell Death and Prolifer-
ative Repair in TRUC Mice
(A) The TRUC epithelium is highly proliferative and epithelial
proliferation increases with time. Cell proliferation index
(BrDU+ cells/[epithelial cells/crypt]) normalized to RAG2/
levels is plotted along the y axis. The mean of six RAG2/
(age 1 month) and five to seven TRUC per time point (age
1–6 months) is shown; error bars represent ± SD.
(B) Representative immunofluorescence micrograph of data
quantitated in (A) showing a hyperproliferative TRUC mucosa
with BrDU staining (red) and DAPI-labeled nuclei (blue). Scale
bar, 25 mm.
(C) Cell proliferation outpaces cell death as TRUC mice age.
Sections from the mice in (A) were stained with the TUNEL
reagent to label dying epithelial cells. The number of TUNEL+
epithelial cells/(epithelial cells/crypt) was then divided by the
Cell Proliferation Index. This ratio normalized to the calculated
value observed for the RAG2/ samples is plotted along the y
axis. The mean value for six RAG2/ (age 1 month) and five to
seven TRUC per time point (age 1–6 months) is shown; error
bars represent ± SD.
(D) Epithelial cell lysates were generated from distal CECs from
TRUC and RAG2/. Each lane represents sample from two
mice, and two separate groups with the indicated pathology
were examined by western blot for Bcl-2, Bak, Bax, and Bcl-xL
levels. Hsp 90 was used as a loading control.
TRUC Colonic Neoplasia Is Dependent
on an Inflammatory Response to
Commensal Bacteria that Is MyD88
Independent and Can Be Blunted by Early,
but Not Late, TNF-a Neutralization
The profound effects on proliferation and apoptosis
observed in TRUC epithelium amidst the com-
plexity of the TRUC inflammatory milieu suggested
that treatment of the underlying inflammation might alter the
development of dysplasia and cancer. We had previously shown
that broad-spectrum antibiotic treatment ameliorated TRUC
colitis by changing but not eliminating the commensal micro-
flora. To determine if altering the commensal microflora would
reduce the incidence of TRUC neoplasia, we undertook a long-
term course (6 months) of continuous antibiotic treatment over
the time period during which TRUC mice develop dysplasia
and cancer. None of the mice in the antibiotic treatment group
developed colitis (Figure 4A, left panel), but 100% of the mice
in the control group had very severe colitis by 6 months of age.
In contrast to the control group, which showed HGD (40% of
cases) and ACA (60% of cases), none of the antibiotic-treated
mice had neoplasia (Figure 4A, right panel). These data suggest
that neoplasia in TRUC mice is dependent on an inflammatory
response that in turn requires the presence of the full comple-
ment of the TRUC commensal microflora.
Typically, the innate immune system senses microbes via
microbial pattern-recognition receptors, of which the Toll-like
receptors (TLRs) are one major family of these. TLRs have
emerged as negative regulators of cancer and TLR stimulation
is now recognized as a driver of tumorigenesis (Rakoff-Nahoum
and Medzhitov, 2009). Therefore, we tested whether loss of
MyD88, a crucial TLR signaling molecule, would affect TRUC
colitis and caCRC as has been shown in the IL-10/ colitis212 Cancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc.
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Figure 4. TRUC Colonic Neoplasia Is Dependent on an Inflammatory Response to Commensal Bacteria that IsMyD88 Independent and Can
Be Blunted by Early, but not Late, TNF-a Neutralization
(A) Six-month-old TRUC mice treated with continuous broad spectrum antibiotics do not develop neoplasia. Histologic colitis score (y axis) and neoplastic
classification (x axis) (LGD, HGD, and ACA). Vancomycin, metronidazole, neomycin, and ampicillin treated (open circles) and water control (shaded circles).
(B) MyD88/ TRUC develop colitis and neoplasia. (left) Histologic colitis scores for 8 week old MyD88/ TRUC (open circles) and TRUC (shaded circles). (right)
Histologic colitis scores (y axis) and distribution of the degree of neoplasia (x axis) for 12 week old MyD88/ TRUC.
(C) Mice treated with anti-TNF-a from 8–12 weeks do not develop neoplasia while isotype control 8–12 week group mice do. Percentage of the population with no
dysplasia, LGD, HGD, and ACA is shown for each group (n = 8 per group).
(D and E) Treatment with anti-TNF-a does not ameliorate colitis or prevent the development of neoplasia in mice treated from 3 to 6 months. Histologic colitis
score (y axis) and distribution of the degree of neoplasia (x axis) is shown (open circles, anti-TNF-a treated; shaded circles, isotype control treated). Each circle
represents an individual mouse.model (Rakoff-Nahoum et al., 2006) and in a carcinogen-treated
IL-10/ caCRC model (Uronis et al., 2009). Remarkably,
MyD88/ TRUC mice developed colitis of similar severity to
TRUC (Figure 4B). Although these mice breed poorly and are
severely immunocompromised, we generated five MyD88/
TRUC mice that survived until 3 months of age. One of the five
mice had submucosal ACA and 3/5 had dysplasia (Figure 4C).
Thus, both inflammation and neoplasia in TRUC appear inde-
pendent of MyD88, suggesting that classical TLR pathways are
not necessary for TRUC caCRC.
We had previously shown that treating TRUC mice from 4–8 or
8–12 weeks of age with anti-TNF-a neutralizing antibody cured
them of their microbe-driven inflammatory colitis. When miceCwere treated from 4–8 weeks with anti-TNF-a or isotype control
antibody, no dysplasia was observed in either group, consistent
with the limited exposure of the epithelium to an inflammatory
milieu. However, 2/8 mice from the isotype control treated 8–
12 week group had LGD and 1/8 mice had HGD, similar to the
prevalence of neoplastic lesions we observed above (Figure 1).
In contrast, none of the eight mice treated with anti-TNF-a anti-
body from 8–12 weeks developed dysplasia (Figure 4D). In
recognition of published results that anti-TNF-a prevented
dysplasia and carcinoma in the dextran sulfate sodium (DSS)/
azoxymethane (AOM) caCRC model even when administered
at late time points well after ACA has developed, we attempted
to treat TRUC mice from 3 to 6 months of age (Popivanovaancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc. 213
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treated and anti-TNF-a-treated cohorts and the four mice dis-
played for each group represent survivors of three independent
experiments. Treatment with anti-TNF-a from 3 to 6 months of
age had no effect on colitis and both the treatment and control
groups had the same number of mice with HGD and ACA
(Figure 4E). Although this small number of animals precludes
a robust interrogation into the differences of the neoplastic
microenvironment in the setting of this intervention, we did
observe modest differences in several cytokines (IL-1b, IL-6,
and IL-18) between anti-TNF and control treated mice
(Figure S1C). Thus the commensal microflora and TNF-a are
central initiators of caCRC, but delayed TNF-a neutralization is
ineffective in halting neoplastic progression because it is unable
to extinguish inflammation at this later stage.
TRUC and TRUC-Associated CRC Is Driven
by Dendritic Cells and Can Be Prevented
by Targeted Reexpression of T-bet in DCs
Innate immune cells play a key role in chronic inflammatory
responses and much attention has been focused on macro-
phages and mast cells as inciters of the neoplastic environment
(Bui and Schreiber, 2007; de Visser et al., 2006; Johansson et al.,
2008). T-bet is not expressed, however, in macrophages or mast
cells (L.H.G., unpublished data; Alcaide et al., 2007). Our
previous work on the TRUC model suggested that T-bet func-
tioned as a repressor of TNF-a in dendritic cells (DCs), but did
not establish that DCs were necessary and sufficient for TRUC
colitis. Two approaches were taken to determine the function
of T-bet expressing DCs. In the first approach, we used the
CD11c diphtheria toxin receptor (DTR) transgene to delete DCs
in TRUC mice. TRUC mice expressing the CD11cDTR transgene
were generated and then served as donors in bone marrow
chimera experiments with TRUC mice as the recipients. After
engraftment (8 weeks), we treated TRUC mice with diphtheria
toxin every other day for 8 weeks to delete their DCs. Although
the diphtheria treatment was toxic (40% of the treatment
cohort died), DC-depleted mice that did survive the treatment
showed no evidence of colitis, whereas controls (TRUC into
TRUC chimeras and PBS-treated CD11c DTR TRUC chimeras)
had colitis (Figure 5A, left panel). As expected, diphtheria toxin
treatment of transgenic bone marrow chimeric mice resulted in
diminished colonic CD11c+ populations documented by indirect
immunofluorescence microscopy (Figure 5A, right panel). Thus
TRUC colitis appears dependent on DCs.
A second complementary approach addressed whether
restoration of T-bet expression in DCs would ameliorate colitis
and hence prevent neoplasia. We generated TRUC mice that
overexpressed T-bet under the control of the CD11c promoter
and verified expression in CD11c+ subsets from the colon and
spleen of the transgenic TRUC mice (Figure 5B). Our previous
published work, using primarily in vitro methodology, suggested
that T-bet functioned as a repressor of TNF-a in DCs. The CD11c
T-bet Tg TRUC had markedly reduced TNF-a levels in colonic
explant cultures performed on mice at 4 weeks of age, suggest-
ing that T-bet functions as a repressor in DCs in vivo (Figure 5C).
Expression of T-bet did vary across the transgenic founders
generated and we found that there was an inverse correlation
between T-bet overexpression and colitis score in the CD11c214 Cancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier IncT-bet Tg TRUC adult progeny of these founders (Figure 5 D).
We set aside a cohort of mice for 6 months to observe the effects
of T-bet overexpression in DCs on the development of inflamma-
tion and neoplasia. As shown in Figure 5E, (25/36) transgenics
had no dysplasia versus (3/48) controls, (4/36) transgenics had
HGD versus (12/48) controls, and (3/35) transgenics had ACA
versus (30/48) controls. The difference between the number of
nonneoplastic and neoplastic cases observed was statistically
significant (p < 0.0001) between the CD11c T-bet transgenic
TRUC and control TRUC. These data establish that DCs are
critical for chronic inflammation in TRUC mice and that overex-
pression of T-bet in DCs rescues TRUC from dysplasia and
cancer.
DISCUSSION
Inflammation is a key contributor to carcinogenesis and chronic
inflammatory diseases, like IBD, initiate complex pathways to
neoplasia. Here we report on a model of inflammation-driven
colonic neoplasia dependent on the transcription factor T-bet
and explore its similarity to human caCRC. TRUC mice provide
unique opportunities to understand the role of innate immunity-
driven inflammation and DCs in caCRC. Despite the intricacy
of the inflammatory environment, selectively targeting one cell
type, the DC, ablated inflammation in TRUC colons. Notably,
selective, targeted overexpression of T-bet to DCs also substan-
tially reduced neoplasia. Although initially discovered as the key
regulator for CD4+ T helper type 1 T cell differentiation, T-bet has
subsequently been found to have important functions in immune
cell types spanning both the adaptive and innate immune system
(Glimcher, 2007). Our group has previously examined the role of
T-bet in the TRAMP prostate cancer and B16 melanoma models
and defined a role for T-bet in limiting metastasis in TRAMP mice
and more specifically mediating NK cell control of metastasis in
the B16 model (Peng et al., 2004; Werneck et al., 2008). T-bet
expression in CRC correlates with increased patient survival
and decreased lymphovascular invasion within the tumor itself
(Pages et al., 2005). T-bet expression in patient CRC samples
is protective and, while expression has understandably been
attributed to admixed T cells, our data that T-bet overexpression
in DCs blunts colonic inflammation and reduces colonic
neoplasia raise interest in the idea that T-bet expression in
DCs may also play a protective role in patients as well. Transcrip-
tion factor targeting has proven elusive as a cancer therapeutic;
however, small molecule microarray-based assays and integrin
antibody-targeted nanoparticles have made engineering thera-
peutics for altering T-bet expression in colonic DCs an achiev-
able therapy for patients (Peer et al., 2008; Vegas et al., 2008).
IBD-driven CRC represents one extreme of how chronic
inflammation shapes a proneoplastic environment. Proinflam-
matory cytokines, such as TNF-a, orchestrate effective defen-
sive mechanisms against pathogens that can become inherently
self-destructive in the acute setting of sepsis, pathogenic when
triggered in response to the commensal microbiota or cross-
reactive self-antigens in IBD and rheumatoid arthritis, or prome-
tastatic in the subclinical inflammation present in numerous solid
tumors (Smith, 2009). TNF was originally characterized by Lloyd
Old in 1975 as a factor secreted by macrophages that killed the
L-929 fibrosarcoma cell line (Old, 1988). Recombinant TNF-a is.
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Figure 5. TRUC Colitis Is Dependent on DCs
and T-bet Overexpression in DCs Reduces
the Prevalence of TRUC Colitis-Associated
Dysplasia and CRC
(A) TRUC colitis is dependent on DCs. CD11c DTR
Tg+ TRUC mice were generated and used as
donors in bone marrow chimera experiments with
TRUC mice as recipients, TRUC bone marrow
was engrafted into irradiated TRUC recipients as
a control. After engraftment (8 weeks), CD11c
DTR Tg+ TRUC chimeric mice were treated every
other day with PBS (shaded circles) or DTX (open
circles) for 8 weeks (left panel). Control TRUC
bone marrow chimeras were DTX treated for
8 weeks (shaded squares) (left panel). Each dot
represents one mouse. 40% of the original DTX-
treated cohort group died during the 8 week course
of treatment. Deletion of CD11c+ DC subsets was
confirmed by indirect immunofluorescence micro-
scopy for CD11c on paraffin-embedded sections
from representative mice from each group. A
selected image from the distal colon is shown for
each group. CD11c, pink; Hoescht, blue. Scale
bars, 50 mm.
(B) T-bet expression in CD11c T-bet Tg+ TRUC
mice. T-bet expression was measured in purified
myeloid colonic cell populations, in CEC popula-
tions, and in splenic cell populations pooled from
15 sex-matched CD11c T-bet Tg+ TRUC mice
without evidence of colitis, using real-time qPCR.
Bars represent the mean values across three
replicate qPCR reactions on the samples and error
bars ± SD.
(C) Restoration of T-bet expression using a CD11c
transgenic cassette reduces colonic explant TNF-a
levels in transgene expressing TRUC mice. TNF-a
ELISA-based protein determinations from colonic
explants from CD11c T-bet Tg+ TRUC and
TRUC, age 4 weeks. Bars represent the mean
value across three sets of explant samples (five
individual mice per group) and error bars ± SD.
(D) T-bet overexpression inversely correlates with
colitis score. qPCR for T-bet expression was per-
formed on cDNA generated from RNA isolated
from paraffin embedded CD11c T-bet Tg+ TRUC
colons andRAG2/ controls. T-bet abundance relative to b-actin and then normalized toRAG2/ levels (y axis) is plotted versus colitis score (x axis). (left panel)
Individual mice depicted by dots (when overlapping, the number of mice is shown above the dot). (right panel) Bars represent the mean values for mice grouped
by colitis score (0, 1–3, 4–6, and 7–9) and error bars represent ± SD.
(E) CD11c T-bet Tg+ TRUC mice have reduced prevalence of dysplasia and carcinoma. Cohorts were aged to 6 months and evaluated for colitis (y axis) and
neoplasia (grouped by histopathology along the x axis), CD11c T-bet Tg+ TRUC (shaded circles, n = 35), and control TRUC (open circles, n = 48).currently in clinical trials for ovarian and head and neck cancer as
well as a number of advanced solid tumors (http://www.cancer.
gov/clinicaltrials). However, TNF-a also may be a culprit in
driving metastasis as recently suggested by the observations
that TNF-a stabilizes Snail via NF-kB activation of the COP9
signalosome2 and that knockdown of Snail inhibited inflamma-
tion-driven breast cancer metastasis (Wu et al., 2009). Clearly,
the relationship between TNF-a and cancer is complex as high-
lighted here. We have previously demonstrated that T-bet
functions as a repressor of TNF-a in DCs and that TNF-a neutral-
ization can both ameliorate and block colitis at its inception and
cure established colitis. Nevertheless, there appear to be thera-
peutic limits to TNF-a blockade in preventing neoplasia in TRUC,
as neutralization from 3–6 months of age did not prevent HGDCand ACA. This observation is in contrast to recent findings in
the DSS/AOM model of caCRC, where late stage CRC was
successfully treated with TNF blockade (Popivanova et al.,
2008). We have previously shown that TRUC CECs cultured
ex vivo demonstrate an increased sensitivity to TNF-a-induced
cell death. However, the cell death and proliferation experiments
in conjunction with the TNF-a colon explant ELISA data suggest
that TRUC CECs may reprogram this sensitivity to TNF-a-
induced cell death. Our studies of TRUC mice, a spontaneous
model of caCRC, suggest that TNF-a in a chronically inflamed
mucosa may initiate a cascade of events that engender
dysplasia and cancer. However, once this process is unleashed
neither blockade of TNF-a nor excess TNF-a is effective in
halting neoplastic progression.ancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc. 215
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driven cancer, other proinflammatory cytokines play central
roles as well. Pleiotropic protumorigenic effects have been
ascribed to IL-6 in a number of epithelial cancers (colon, breast,
lung, and liver) (Lin and Karin, 2007). More recently, IL-6 has
been shown to be critical for the development of caCRC via its
antiapoptotic effects and induction of hypoxia genes via the
IL-6 downstream effector STAT3 in the colonic epithelium (Gri-
vennikov et al., 2009). Furthermore, carcinoma-produced
factors are adept at eliciting high levels of host myeloid IL-6
and TNF-a (Kim et al., 2009). IL-1b, like TNF-a, can initiate proin-
flammatory cascades driving the production of proinflammatory
mediators (COX-2 and iNOS), cytokines (IL-6), growth factors,
adhesion molecules, and matrix metalloproteinases. Numerous
cytokines trigger mediators aimed at the resolution phase of
injury and these growth factors and proteases may be construed
as healing. However, in a chronically inflamed mucosa the
epithelium is altered and compromised in appropriate signal
processing. In our experiments, we show clear evidence of aneu-
ploidy, ROS, and DNA adducts prior to the histologic diagnosis
of dysplasia or cancer. The importance of DNA repair mecha-
nisms in response to reactive oxygen and nitrogen species-
induced DNA damage was elegantly demonstrated in the setting
of alkyladenine DNA glycosylase (a major DNA repair enzyme)
deficiency in inducible mouse models of gastritis and colon
cancer (Meira et al., 2008). A model put forth in that study
emphasizes both the importance of proinflammatory effectors
and epithelial cells with DNA alterations for inflammatory-associ-
ated neoplasia. While cytokines, inflammatory mediators, and
DNA damage may all be essential for caCRC, the inciting event
rests in the host’s response to the commensal microbiota.
There is a growing appreciation for host-commensal interrela-
tionships in colon cancer. Genetic deletion of TLR4, which
signals through MyD88, protects mice from CaCRC induced
by DSS/AOM. Several patients with CaCRC have increased
TLR4 epithelial expression and AOM-induced CRC in IL-10/
mice is commensal and MyD88 dependent (Fukata et al., 2007;
Uronis et al., 2009). The innate immune adaptor molecule
MyD88 controls the expression of many epithelial genes influ-
encing tumor development in the APC/min- mouse model and
in carcinogen (AOM)-induced colon cancer (Rakoff-Nahoum
and Medzhitov, 2007). However, our results that TRUC colitis
and caCRC are MyD88 independent suggest that not all caCRC
is dependent on MyD88. Commensal microbial signals may
act via TLR pathways that signal to NF-kB through TRIF or
non-TLR pathways, driven by glycan-based PAMPs that bind
C-type lectin receptors and activate Syk, resulting in NF-kB acti-
vation via Card9, as is the case for Dectin-1 (Ruland, 2008), or via
intracellular bacterial-derived products that activate the NOD1/2
pathway. Identification of the microbes driving inflammation in
TRUC will hopefully inform our understanding of the pathogen
recognition receptor pathways they trigger.
Our experiments provide insight into the role of T-bet and the
innate immune system in colon cancer. We show that a complex
and proneoplastic inflammatory environment can be ablated by
deletion of DCs. Furthermore, we demonstrate that overexpres-
sion of the transcription factor T-bet rescues colitic mice from
caCRC. In conclusion, we present a robust model of caCRC
that provides insight into both disease pathogenesis and thera-216 Cancer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Incpeutic approaches and also furnishes ample opportunities for
basic scientific discovery and preclinical testing.
EXPERIMENTAL PROCEDURES
Generation of TRUC Mice and CD11c T-bet
IRES eGFP Tg T-bet/ 3 RAG2/ Mice
Mice were housed in microisolator cages in the barrier facility of the Harvard
School of Public Health. Animal studies and experiments were approved
and carried out according to Harvard University’s Standing Committee on
Animals and National Institutes of Health guidelines for animal use and care.
Mice in the colony are specific pathogen free and are negative forHelicobacter
hepaticus, bilis, and muridarum.
Mice with deletion of T-bet and RAG2 and their genotyping have been
described previously (Lugo-Villarino et al., 2005).
The CD11c expression cassette was generated in the laboratory of
D. Littman and a T-bet IRES eGFP construct was subcloned into it. CD11c
T-bet IRES eGFP transgenic mice were generated by injection of this linearized
construct into T-bet/ RAG2/ deficient embryos and implanted into
pseudo-pregnant TRUC mice to preserve the TRUC microbiota. Mice were
genotyped for transgene expression using a modified protocol from the Jack-
son Laboratory. Primer sets were as follows: CTAGGCCACAGAATTGAAAG
ATCT, GTAGGTGGAAATTCTAGCATCATCC, AAGTTCATCTGCACCACCG,
and TCCTGAAGAAGATGGTGCG (GFP and endogenous IL-2).
Founder mice were screened for expression using flow cytometry for GFP
fluorescence of CD11c+ subsets from blood, spleen, and colon. Mice were
subsequently screened by real-time qPCR for T-bet expression from RNA
isolated from spleen and colon cell subsets (generated using MACS selection)
using the primers CAACAACCCCTTTGCCAAAG and TCCCCCAAGCAGTTG
ACAGT.
T-bet/ RAG2/ were bred to the MyD88-deficient mice (obtained from
the laboratory of D. Goldstein with permission from S. Akira).
Broad-Spectrum Antibiotic Treatment of TRUC Colitis
Mice were treated for 6 months with ampicillin (1 g/l; Roche), vancomycin
(500 mg/l; Henry Schein, Inc. [Hospira, Inc.]), neomycin sulfate (1 g/l; Sigma
[Teva Pharmaceuticals]), and metronidazole (1 g/l; Sigma; solubilized with
15 ml of 0.1 N acetic acid/liter) dissolved in their autoclaved drinking water
acid and fluid intake was monitored.
Generation of CD11c DTR GFP TRUC Mice
CD11c DTR eGFP Tg mice from the Jackson Laboratory were crossed to
T-bet/ RAG2/ mice and genotyped for presence of the transgene as per
Jackson Laboratory protocol. High expressing mice (by analysis of CD11c+
GFP+ population from peripheral blood) were bred and selected as donors
in bone marrow chimera experiments.
TRUC mice were irradiated with 800 rads and received CD11c DTR eGFP
Tg+ TRUC or TRUC bone marrow 2 hr after irradiation. After engraftment
(8 weeks), transgene expression was tested by peripheral blood flow cytome-
try and mice were treated with PBS or 10 ng/gm mouse weight of diphtheria
toxin (Sigma) every other day for 8 weeks.
Histology
Colons were removed from mice after termination and dissected free from the
anus to distal to the cecum. Colonic contents were removed and colons
cleaned with PBS prior to fixation in 4% PFA or 10% neutral buffered formalin
followed by routine paraffin embedding. After paraffin embedding, 0.5 mm
sections were cut and stained with hematoxylin and eosin or as noted.
Sections were examined and colitis was scored in a blinded fashion
(with respect to genotype and experimental protocol) by one of the authors
(J.N.G.). Each of four histologic parameters was scored as absent (0), mild
(1), moderate (2), or severe (3): mononuclear cell infiltration, polymorphonu-
clear cell infiltration, epithelial hyperplasia, and epithelial injury, similar to
previous studies (Neurath et al., 2002). For cancer incidence studies, J.N.G.
examined all tissues for dysplasia and CRC in a blinded fashion on two inde-
pendent occasions. Assessment for dysplasia and cancer was based on the
criteria set forth in the Mouse Models of Intestinal Cancers consensus report:.
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grade, invasion level, presence of desmoplasia, and presence of irregular
architecture (gland crowding, solid nests of cells versus single cells, irregularity
or cribiforming, presence of lateral spread, and loss of acini) (Boivin et al.,
2003).
Immunohistochemistry
Paraffin-embedded colon sections were deparaffinized, rehydrated, and pre-
treated with hydrogen peroxidase in PBS buffer. Heat-induced antigen
retrieval was performed.
After blocking with the appropriate antisera in blocking buffer, sections were
incubated with anti-PCNA (1:100), anti-b-catenin (BD Biosciences clone 14/b-
catenin; 1:900 dilution), anti-p53 (clone CM5 [1:400]), or anti-COX-2 (Santa
Cruz clone c-20; 1:50 dilution) for 1 hr at room temperature. After incubation
with HRP-conjugated secondary antibody and tyramide amplification followed
by streptavidin-HRP, positive signals were visualized by DAB kit and counter-
stained with hematoxylin.
Quantitation
COX-2
Total crypts and COX-2+ crypts were scored from three TRUC mice with and
three without neoplasia. Four lower power (103 objective), contiguous fields
spanning the distal colons were scored.
p53
Total crypt number, number of crypts with p53 staining, and number of positive
cells per crypt were quantitated across two low power (103 objective) fields
spanning the distal colon for nine TRUC mice with and nine without carcinoma
and dysplasia.
Isolation of RNA from Paraffin-Embedded Tissues
RNA was isolated from microdissected paraffin-embedded tissues using the
RecoverAll Total Nucleic Acid Isolation Kit according to the manufacturer’s
instructions.
Generation of cDNA from RNA
cDNA was generated from isolated RNA using the Invitrogen iScript kit.
Real-Time qPCR
Real-time qPCR was carried out using ABI SyBR reagent on an ABI 7700 or
Stratagene Mx3005p using SYBR or POWER SYBR green master mix from
ABI. HPRT, unless otherwise noted, was the housekeeping gene used.
Primer Design
Unless otherwise noted, primers used were from validated sets designed by
Primer Bank (http://pga.mgh.harvard.edu/primerbank/index.html).
BrDU Staining
Mice were injected with 200 ml BrDU i.p. and sacrificed after 2 hr. Colons were
subsequently fixed for 2 hr in neutral-buffered formalin, placed in 70% EtOH
overnight, embedded, and stained for BrDU using the BrDU detection kit
from BD Biosciences. Sections were counterstained with DAPI and for assess-
ment of cell death in conjunction with cell proliferation; sections were stained
using the Roche TUNEL in situ death fluorescence kit.
Colonic Crypt Isolation
In brief, cells were isolated from cleaned minced colons using HBBS with 1 mM
EDTA/1 mM EGTA as previously described (Garrett et al., 2007).
p53 Activity Assays
Colonic crypts were isolated as above from the distal colon of RAG2/ mice
or colitic or neoplastic segments of TRUC colons. CECs were treated with
doxorubicin at 0.5 mg/ml for 8 hr or vehicle alone. Twenty segments were
pooled per group to generate a sufficient number of cells for RNA isolation
or nuclear extracts. Two separate isolations and treatments of the CECs
were performed and data represent the mean ± SD across these groups.
RNA was isolated and cDNA was generated as described. b-Actin was the
housekeeping gene used for relative abundance calculations and a fold
change was calculated for p21 and APAF1 induction relative to detectionCalevels in control-treated samples. For DNA binding activity, nuclear extracts
were generated as per the manufacturer’s instructions for the Duoset IC intra-
cellular human/mouse p53 activity assay with the exception that lysis buffers A
and B were prepared with Roche protease and PhosSTOP inhibitor cocktail
tablets and 20 mg of extract was used per well.
Aneuploidy Analysis
Colonic crypt cells were isolated and cells were then fixed in ice-cold ethanol
at a final concentration of 70% using vigorous vortexing, RNase treated,
stained with anti-CD45-APC antibody to exclude any myeloid contaminating
subsets, and stained with propidium iodide. Data were acquired using a BD
LSRII flow cytometer and the flow cytometer was calibrated for DNA ploidy
analysis using the BD DNA QC particle kit. The HT-29 cell line was used as
a positive control for aneuploid populations. Data were analyzed using ModFIT
software (Clausen et al., 2001).
Measurement of Reactive Oxygen Species
Colons were removed after sacrifice and cleaned distal colons were divided
into three segments and placed in a buffer of 1 mM CaCl2 and 5 mM glucose.
Colonic segments were weighed and then placed into luminol assay buffer
(0.045 g luminol in PBS). After a 3 min incubation, luminescence was measured
using a luminometer. The average across all segments constituted the value
for each mouse. After weight correction, values were averaged for six to
nine mice per time point (Millar et al., 1996).
Western Blots
CECs were isolated and lysates were generated using RIPA buffer in the pres-
ence of protease inhibitors. Protein lysates were resolved using SDS-PAGE
and transferred to PVDF membrane using a Bio-Rad Wet transfer apparatus.
Blots were probed with antibodies directed against Bcl-2, Bax, Bak, Bcl-xL,
and Hsp90 (all from Santa Cruz Biotechnology, Inc.). After incubation with
the appropriate HRP-conjugated secondary antibody, we used ECL to
develop the blots.
Measurement of DNA Adducts
DNA was extracted from CECs from the distal colon using the QIAGEN
genomic DNA extraction kit as per the manufacturer’s protocol. Samples
were processed as per the manufacturer’s instructions for the high sensitivity
8-OHdG ELISA kit K0G-HS10E with the following exceptions. Nuclease P1
and alkaline phosphatase digestions were performed in an An02 hood. After
processing, DNA-digested samples from six to nine mice per time point
were pooled and subjected to quantitation by ELISA in triplicate.
Anticytokine Therapy
Anti-TNF-a (clone TN3-19.12), a hamster anti-mouse TNF-a neutralizing IgG1,
and isotype control were a kind gift of R. Schreiber and purchased from Leinco
Technologies, Inc. Fifteen micrograms per gram of mouse weight of antibody
was injected i.p. every 7 days for durations as noted. Mice were sacrificed
1 week following the last injection.
Colon Explant Culture
Explant cultures were carried out following a modification of previously
described procedures (Rakoff-Nahoum et al., 2004). One centimeter segments
of the distal colon were washed in HBBS containing penicillin, streptomycin,
and gentamicin. The segments were cultured in 48 well flat bottom plates
with complete RPMI media supplemented with penicillin, streptomycin, and
gentamicin. Media was collected after 4 hr and centrifuged to remove debris.
After centrifugation, the supernatant was aliquoted and stored at 80C.
Measurement of Cytokines
Cytokines were measured in culture supernatants utilizing SearchLight high
dynamic range imaging and analysis unless otherwise indicated. For IL-10
and TNF-a, the mouse OptEIA ELISA kit (BD Biosciences) was used as per
the manufacturer’s instructions.
Statistical Analysis
Statistical analyses were performed using the Mann-Whitney U nonparametric
test for ordinal data. Error bars represent ± SD unless otherwise noted.ncer Cell 16, 208–219, September 8, 2009 ª2009 Elsevier Inc. 217
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